PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kühn-Steven, A.* ; Gensch, K.* ; Haust, M.* ; Schneider, S.W.* ; Bonsmann, G.* ; Gaebelein-Wissing, N.* ; Lehmann, P.* ; Wons, A.* ; Reitmeir, P. ; Ruland, V.* ; Luger, T.A.* ; Ruzicka, T.*

Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial.

J. Am. Acad. Dermatol. 65, 54-64 (2011)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
BACKGROUND: Topical calcineurin inhibitors are licensed for the treatment of atopic dermatitis; however, the efficacy of tacrolimus in cutaneous lupus erythematosus (CLE) has only been shown in single case reports. OBJECTIVE: In a multicenter, randomized, double-blind, vehicle-controlled trial, we sought to evaluate the efficacy of tacrolimus 0.1% ointment for skin lesions in CLE. METHODS: Thirty patients (18 female, 12 male) with different subtypes of CLE were included, and two selected skin lesions in each patient were treated either with tacrolimus 0.1% ointment or vehicle twice daily for 12 weeks. The evaluation included scoring of clinical features, such as erythema, hypertrophy/desquamation, edema, and dysesthesia. RESULTS: Significant improvement (P < .05) was seen in skin lesions of CLE patients treated with tacrolimus 0.1% ointment after 28 and 56 days, but not after 84 days, compared with skin lesions treated with vehicle. Edema responded most rapidly to tacrolimus 0.1% ointment and the effect was significant (P < .001) in comparison to treatment with vehicle after 28 days. Clinical score changes in erythema also showed remarkable improvement (P < .05) after 28 days, but not after 56 and 84 days. Moreover, patients with lupus erythematosus tumidus revealed the highest degree of improvement. None of the patients with CLE demonstrated any major side effects. LIMITATIONS: The study was limited by the small sample size. CONCLUSION: Explorative subgroup analyses revealed that topical application of tacrolimus 0.1% ointment may provide at least temporary benefit, especially in acute, edematous, non-hyperkeratotic lesions of CLE patients, suggesting that calcineurin inhibitors may represent an alternative treatment for the various disease subtypes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.274
2.200
43
63
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords autoimmune disease; calcineurin inhibitors; cutaneous lupus erythematosus; randomized trial; tacrolimus ointment; treatment
Language english
Publication Year 2011
HGF-reported in Year 2011
ISSN (print) / ISBN 0190-9622
e-ISSN 1097-6787
Journal Journal of the American Academy of Dermatology : JAAD
Quellenangaben Volume: 65, Issue: 1, Pages: 54-64 Article Number: , Supplement: ,
Publisher Elsevier
Reviewing status Peer reviewed
Institute(s) Institute of Health Economics and Health Care Management (IGM)
POF-Topic(s) 30202 - Environmental Health
Research field(s) Genetics and Epidemiology
PSP Element(s) G-505300-002
PubMed ID 21501887
DOI 10.1016/j.jaad.2010.03.037
Scopus ID 79958790928
Erfassungsdatum 2011-08-01
[➜Report correction]